Literature summary for 3.1.4.46 extracted from

Toropainen, M.; Raitolehto, A.; Henckaerts, I.; Wauters, D.; Poolman, J.; Lestrate, P.; Kaeyhty, H.
Pneumococcal Haemophilus influenzae protein D conjugate vaccine induces antibodies that inhibit glycerophosphodiester phosphodiesterase activity of protein D (2008), Infect. Immun., 76, 4546-4553.

Search for more literature for 3.1.4.46

Application

Application	Comment	Organism
medicine	to study if membrane protein D (PD)-induced protection against NTHI as a vaccine is due to antibodies that inhibit or neutralize its enzymatic activity, a GlpQ enzyme inhibition assay is developed, and serum samples collected from Finnish infants before and after Pnc-PD vaccination are analyzed for enzyme inhibition and anti-PD IgG antibody concentration. Before vaccination at age 2 months, the majority (84%) of infants has no detectable anti-PD IgG antibodies, and all are enzyme inhibition assay negative. At age 13 to 16 months, all infants receiving three or four doses of Pnc-PD have detectable anti-PD IgG antibodies and 36% of the infants receiving three doses and 26% of the infants receiving four doses of Pnc-PD are inhibition assay positive	Haemophilus influenzae

Localization

Localization	Comment	Organism	GeneOntology No.	Textmining

Organism

Organism	UniProt	Comment	Textmining
Haemophilus influenzae	-	-	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
L-alpha-glycerophosphorylcholine + H2O	-	Haemophilus influenzae	sn-glycerol 3-phosphate + choline	-	?

Synonyms

Synonyms	Comment	Organism
GlpQ	-	Haemophilus influenzae
glycerophosphodiester phosphodiesterase	-	Haemophilus influenzae
outer membrane protein D	-	Haemophilus influenzae

Temperature Optimum [°C]

Temperature Optimum [°C]	Temperature Optimum Maximum [°C]	Comment	Organism
22	-	assay at	Haemophilus influenzae

pH Optimum

pH Optimum Minimum	pH Optimum Maximum	Comment	Organism
9	-	assay at	Haemophilus influenzae

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)